Astrazeneca PLC (AZN): Price and Financial Metrics


Astrazeneca PLC (AZN): $56.81

-0.65 (-1.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

AZN POWR Grades


  • AZN scores best on the Quality dimension, with a Quality rank ahead of 88.67% of US stocks.
  • The strongest trend for AZN is in Momentum, which has been heading down over the past 31 weeks.
  • AZN's current lowest rank is in the Momentum metric (where it is better than 11.83% of US stocks).

AZN Stock Summary

  • AZN has a market capitalization of $150,851,889,762 -- more than approximately 98.49% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Astrazeneca Plc is reporting a growth rate of 87.89%; that's higher than 82.65% of US stocks.
  • In terms of volatility of its share price, AZN is more volatile than only 9.49% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Astrazeneca Plc, a group of peers worth examining would be LIN, BMY, AMGN, AXP, and UNP.
  • AZN's SEC filings can be seen here. And to visit Astrazeneca Plc's official web site, go to www.astrazeneca.com.

AZN Valuation Summary

  • AZN's price/earnings ratio is 38.6; this is 13.53% higher than that of the median Healthcare stock.
  • Over the past 243 months, AZN's price/sales ratio has gone up 2.9.
  • AZN's price/sales ratio has moved up 2.9 over the prior 243 months.

Below are key valuation metrics over time for AZN.

Stock Date P/S P/B P/E EV/EBIT
AZN 2020-09-17 5.7 12.0 71.8 41.1
AZN 2018-09-18 4.2 7.5 37.3 33.1
AZN 2015-08-19 3.3 4.6 71.4 43.2
AZN 2012-04-16 1.7 2.5 5.8 4.5
AZN 2009-10-29 2.1 3.7 9.7 6.4
AZN 2006-07-17 3.7 6.6 17.5 11.2

AZN Stock Price Chart Interactive Chart >

Price chart for AZN

AZN Price/Volume Stats

Current price $56.81 52-week high $60.93
Prev. close $57.46 52-week low $46.48
Day low $56.81 Volume 10,798,800
Day high $57.43 Avg. volume 10,890,897
50-day MA $58.06 Dividend yield 3.24%
200-day MA $53.23 Market Cap 149.10B

Astrazeneca PLC (AZN) Company Bio


AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.

AZN Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$56.81$45.15 -21%

Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 49th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. In terms of the factors that were most noteworthy in this DCF analysis for AZN, they are:

  • Astrazeneca Plc's weighted average cost of capital (WACC) is 9%; for context, that number is higher than only 18.85% of tickers in our DCF set.
  • Relative to other stocks in its sector (Healthcare), Astrazeneca Plc has a reliance on debt greater than 69.78% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-23%
1%-22%
2%-21%
3%-21%
4%-20%
5%-19%

Want more companies with a valuation profile/forecast similar to that of Astrazeneca Plc? See MEDP, MMSI, STE, PBH, and EGRX.


AZN Latest News Stream


Event/Time News Detail
Loading, please wait...

AZN Latest Social Stream


Loading social stream, please wait...

View Full AZN Social Stream

Latest AZN News From Around the Web

Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.

Israel to offer COVID-19 vaccines to at-risk children - Jerusalem Post

narvikk/iStock via Getty Images Israel has greenlighted the administration of COVID-19 vaccines to children aged 5 – 11 years who are at risk of advancing to the severe form of the disease, The Jerusalem Post reported. “There are special situations in which vaccination can be considered for children at these ages,” the country’s...

Seeking Alpha | July 27, 2021

Novavax Stock May Not Get the Delta Varient Bump Investors Need

While NVAX stock may enjoy increased relevance on paper due to the delta variant, investors should think about the bigger picture.

Josh Enomoto on InvestorPlace | July 26, 2021

President of the Nation Multimedia Group denounces social inequality in Buriram

President of the Nation Multimedia Group denounces social inequality in Buriram In a Facebook post, Shine Bunnag, chairman of the Nation Multimedia Group (NMG), asked why Burirams police officers received a third AstraZeneca shot while 38 million Thais did not even get one. He posted his comment on Facebook after seeing a photo on social [] The post President of the Nation Multimedia Group denounces social inequality in Buriram appeared first on Pattaya News - PattayaToday .

Pattaya Today | July 26, 2021

Millions of Pfizer, AstraZeneca COVID-19 vaccines to arrive by mid-August Akufo-Addo

Ghana will by mid-August receive millions of COVID-19 vaccines through the COVAX facility to ramp up the availability of vaccines, to inoculate all adult population of the country by the end of 2021. About one million Pfizer vaccines from the United States of America, 229,670 Pfizer vaccines from the African Union, and 249,000 AstraZeneca vaccines The post Millions of Pfizer, AstraZeneca COVID-19 vaccines to arrive by mid-August Akufo-Addo appeared first on Ghana Business News .

Ghana Business News | July 26, 2021

Sinovac and AstraZeneca vaccine cocktail highly effective, says Thai research

BANGKOK: Thailands Centre of Excellence in Clinical Virology, at the Faculty of Medicine of Chulalongkorn University, reported today (July 26) that a vaccine cocktail of Sinovac and AstraZeneca is highly effective.

The Phuket News | July 26, 2021

Read More 'AZN' Stories Here

AZN Price Returns

1-mo -5.43%
3-mo 10.59%
6-mo 14.40%
1-year 3.58%
3-year 62.56%
5-year 98.62%
YTD 15.79%
2020 3.06%
2019 35.58%
2018 13.77%
2017 33.10%
2016 -15.90%

AZN Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full AZN Dividend History

Continue Researching AZN

Here are a few links from around the web to help you further your research on Astrazeneca Plc's stock as an investment opportunity:

Astrazeneca Plc (AZN) Stock Price | Nasdaq
Astrazeneca Plc (AZN) Stock Quote, History and News - Yahoo Finance
Astrazeneca Plc (AZN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9429 seconds.